Real Housewives of Miami Star Guerdy Abraira Opens up About Her Breast Cancer Journey
Why It Matters
By spotlighting genomic testing and early detection, Abraira’s story can drive higher screening rates and empower patients to make data‑driven treatment choices, potentially lowering breast‑cancer mortality.
Key Takeaways
- •Breast cancer affects 1 in 8 women worldwide
- •Oncotype DX test predicts recurrence risk and chemo benefit
- •Test scores guide personalized treatment decisions, including radiation
- •Early detection and self‑advocacy improve outcomes for patients
- •Celebrities can raise awareness and encourage testing among their followers
Summary
Reality‑TV star Guerdy Abraira opened up about her breast‑cancer diagnosis, noting that one in three people worldwide will face cancer and one in eight women develop breast cancer.
She explained how her oncologist used the Oncotype DX genomic assay, which scores tumors from zero to 100 to estimate recurrence risk and determine whether chemotherapy adds benefit, effectively turning treatment into a menu of options.
Abraira described the test as a “menu” and urged viewers to ask questions, saying, “Give me the full menu. Keep it simple, stupid,” emphasizing self‑advocacy and prompt medical attention.
Her candid story leverages celebrity influence to boost screening awareness, reminding women that early detection and personalized testing can dramatically improve survival odds.
Comments
Want to join the conversation?
Loading comments...